 DARTMOUTH, Nova Scotia CAMBRIDGE, Mass.--BUSINESS WIRE--- IMV DeliveryPlatform--IMV Inc. NASDAQ: IMV; TSX: IMV, a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies against difficult-to-treat cancers, today announced that the immunotherapeutic capabilities of its DPX delivery platform will be featured in two e-poster presentations at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics October 7-10, 2021. Collectively, these data demo 